In this drug repurposing network analysis and retrospective case-control study, an Alzheimer disease (AD) endophenotype model was made using data from large-scale amyloid or tauopathy genome-wide association studies. Drugs approved by the United States Food and Drug Administration were evaluated for their effect on the AD endophenotype.
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
Adlarity is a once-weekly transdermal formulation of donepezil.
The FDA has granted Breakthrough Therapy designation to gantenerumab, an anti-amyloid beta antibody, for the treatment of Alzheimer disease.
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.
The investigational adeno-associated virus mediated gene therapy is being developed to deliver the protective APOE2 gene to the CNS.
Adverse financial events seen years before diagnosis and become more prevalent after diagnosis
